DirectSens’ Market-Leading LactoSens ® Biosensor Technology Acquired by Kerry Group P.L.C.
DirectSens, a pioneer in next generation biosensor technology, announces the acquisition of its LactoSens® technology by Kerry Group, a global leader in taste and nutrition. The acquisition of LactoSens® reflects DirectSens’ success in developing end-to-end biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes. As an indispensable analytical tool, LactoSens® will work alongside Kerry Group’s ingredient solutions, enabling a more integrated offering for food manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105399369/en/
LactoSens®, Industry Gold Standard Biosensor Kit. Developed and manufactured by DirectSens in Vienna, AUSTRIA, © DirectSens GmbH 2024
“We’re excited to bring LactoSens® into Kerry Group’s portfolio to add a new element to our offering, as we fully integrate LactoSens® into our broader solutions for the food and beverage industry.” — Ronan Moloney, Vice President Enzymes, Kerry Group
Proven track record with global success of LactoSens®
Since its introduction, 8 years ago, LactoSens® has become the industry’s preferred solution for fast, accurate, and cost-effective lactose detection. It is widely used in food and beverage manufacturing, enabling producers to meet stringent regulatory requirements while running their processes efficiently. Its real-time analysis capabilities give manufacturers a competitive edge, solidifying LactoSens® as a market leader.
DirectSens’ Market-Leading Enzyme Engineering and BioSensor technology
For DirectSens, this acquisition proves the market value of its biosensor technology. “This deal underscores the quality of our biosensor technology and manufacturing capabilities. We will continue to execute on our vision to develop and deliver fast and precise biosensor solutions for key analytes to the global marketplace.” said Dr. Christoph Sygmund, CEO of DirectSens.
As the trusted contract manufacturer, DirectSens will continue to ensure the high-quality production of LactoSens®, upholding the product’s established market reputation. This acquisition reinforces DirectSens’ position as a key innovator in the biosensor industry. Excited by this success, the DirectSens team, with its dedicated and passionate individuals, is looking forward to continuing to create new products such as OatSens®, LactaZyme®, XPressGT®, and to foster collaborations with valued partners.
About DirectSens
DirectSens was founded in 2013 in Vienna, Austria, as a biotech company. Specializing in the development of biosensors, DirectSens provides innovative bioanalytical solutions. Press release.
About Kerry Group
Kerry Group is a world leader in taste and nutrition, serving the food, beverage, and pharmaceutical markets. With a commitment to innovation, Kerry Group helps its customers create sustainable, delicious, and healthy products for consumers worldwide. See related Press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105399369/en/
Contacts
Gina Gazzari office@directsens.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom